Xifaxan
Product Images NDC 69189-0309

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Xifaxan (NDC 69189-0309). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avera Mckennan Hospital, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Rifaximin 200 mg Tablet (6918903091)

This is a description of a medication called Rifaximin, also known as Xifaxan. It comes in the form of a 200mg tablet manufactured by Salix Pharm with the lot number NWHF. The medication has been assigned a hospital lot number of APF15E07-AA and has an expiration date of 05/06/2016. The National Drug Code (NDC) for this medication is 6918903091. The medication is associated with the Avera McKennan hospital in Sioux Falls, South Dakota.*

FDA Label Image

Figure 3 (Figure3)

This appears to be a description of a study design for a trial involving different treatments and phases. The design includes screening, treatment phases, maintenance phases, and follow-up phases. There is also mention of obtaining a daily/weekly symptom diary. Further information is not available.*

FDA Label Image

Chemical Structure (Image 01)

FDA Label Image

Figure 1 (Image 02)

This appears to be a graph or chart displaying data related to a study or clinical trial involving a medication called XIFAXAN. The graph shows the proportion of patients without breakthrough HE over time (measured in days post-randomization), with a hazard ratio of 0.421 and a 95% confidence interval. Additional information may be available in the original source material.*

FDA Label Image

Figure 2 (Image 03)

The text describes a graph showing the proportion of patients who did not require hospitalization related to hepatic encephalopathy (HE) over time. The graph shows data for two groups, one of which was given a placebo. The hazard ratio and confidence interval are also provided, along with a p-value. The graph covers a period of time from day 0 (post-randomization) to an unclear endpoint.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.